Development and validation of RSClin N plus tool for hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive breast cancer

被引：0
|
作者：
Pusztai, Lajos
Hoag, Jess R.
Albain, Kathy S.
Barlow, William E.
Stemmer, Salomon M.
Meisner, Allison
Hortobagyi, Gabriel N.
Shak, Steven
Hayes, Daniel F.
Rae, James M.
Baehner, Frederick
Sharma, Priyanka
Kalinsky, Kevin
机构：
[1] Yale Univ, Canc Ctr, New Haven, CT USA
[2] Exact Sci, Redwood City, CA USA
[3] Loyola Univ, Chicago Stritch Sch Med, Cardinal Bernardin Canc Ctr, Maywood, IL USA
[4] Canc Res & Biostat CRAB, Seattle, WA USA
[5] Rabin Med Ctr, Petah Tiqwa, Israel
[6] Fred Hutchinson Canc Ctr, Div Publ Hlth Sci, Seattle, WA USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX USA
[8] Univ Michigan Hlth Syst, Comprehens Canc Ctr, Ann Arbor, MI USA
[9] Michigan Med, Ann Arbor, MI USA
[10] Univ Kansas, Canc Ctr, Westwood, KS USA
[11] Emory Univ, Winship Canc Inst, Atlanta, GA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
508
引用
收藏
页数：1
相关论文
共 50 条
  • [21] APOBEC signature, clinical characteristics, and outcome in hormone receptor-positive (HR+) HER2-negative (HER2-) breast cancer (BC) patients (pts) in real-world data (RWD)
    Chumsri, Saranya
    Raskina, Kira
    Sammons, Sarah
    Alder, Laura
    Danziger, Natalie
    Schrock, Alexa B.
    McGregor, Kim
    Sokol, Ethan
    [J]. CANCER RESEARCH, 2022, 82 (04)
  • [22] Efficacy and safety of ribociclib (LEE011) + letrozole in elderly patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) in MONALEESA-2
    Sonke, G. S.
    Hart, L. L.
    Campone, M.
    Erdkamp, F.
    Janni, W.
    Verma, S.
    Villanueva, C.
    Jakobsen, E.
    Alba, E.
    Wist, E.
    Favret, A. M.
    Bachelot, T.
    Hegg, R.
    Wheatley-Price, P.
    Souami, F.
    Sutradhar, S.
    Miller, M.
    Germa, C.
    Burris, H. A.
    [J]. EUROPEAN JOURNAL OF CANCER, 2017, 72 : S1 - S2
  • [23] Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy
    Du, L.
    Yau, C.
    Brown-Swigart, L.
    Gould, R.
    Krings, G.
    Hirst, G. L.
    Bedrosian, I
    Layman, R. M.
    Carter, J. M.
    Klein, M.
    Venters, S.
    Shad, S.
    van der Noordaa, M.
    Chien, A. J.
    Haddad, T.
    Isaacs, C.
    Pusztai, L.
    Albain, K.
    Nanda, R.
    Tripathy, D.
    Liu, M. C.
    Boughey, J.
    Schwab, R.
    Hylton, N.
    DeMichele, A.
    Perlmutter, J.
    Yee, D.
    Berry, D.
    van't Veer, L.
    Valero, V.
    Esserman, L. J.
    Symmans, W. F.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 (05) : 642 - 651
  • [24] DOSE-DEPENDENT RELATION BETWEEN METFORMIN AND THE RISK OF HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE (HR+/HER2-) BREAST CANCER AMONG POSTMENOPAUSAL WOMEN WITH TYPE-2 DIABETES
    Chikermane, S.
    Trivedi, M., V
    Sharma, M.
    Abughosh, S. M.
    Aparasu, R. R.
    Johnson, M. L.
    [J]. VALUE IN HEALTH, 2021, 24 : S43 - S43
  • [25] EndoPredict(R) in early hormone receptor-positive, HER2-negative breast cancer
    Almstedt, K.
    Mendoza, S.
    Otto, M.
    Battista, M. J.
    Steetskamp, J.
    Heimes, A. S.
    Krajnak, S.
    Poplawski, A.
    Gerhold-Ay, A.
    Hasenburg, A.
    Denkert, C.
    Schmidt, M.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2020, 182 (01) : 137 - 146
  • [26] Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the lines
    Matutino, A.
    Joy, A. A.
    Brezden-Masley, C.
    Chia, S.
    Verma, S.
    [J]. CURRENT ONCOLOGY, 2018, 25 : S131 - S141
  • [27] Sacituzumab govitecan for hormone receptor-positive HER2-negative advanced breast cancer
    Garrigos, Laia
    Camacho, Daniela
    Perez-Garcia, Jose Manuel
    Llombart-Cussac, Antonio
    Cortes, Javier
    Antonarelli, Gabriele
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2024,
  • [28] Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer
    Lopez-Tarruella, Sara
    Jerez, Yolanda
    Marquez-Rodas, Ivan
    Echavarria, Isabel
    Martin, Miguel
    [J]. FUTURE ONCOLOGY, 2017, 13 (24) : 2137 - 2149
  • [29] Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib plus letrozole in hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC).
    Hortobagyi, Gabriel N.
    Stemmer, Salomon M.
    Burris, Howard A.
    Yap, Yoon Sim
    Sonke, Gabe S.
    Paluch-Shimon, Shani
    Campone, Mario
    Petrakova, Katarina
    Blackwell, Kimberly L.
    Winer, Eric P.
    Janni, Wolfgang
    Verma, Sunil
    Conte, Pier Franco
    Arteaga, Carlos L.
    Cameron, David A.
    Xuan, Fengjuan
    Miller, Michelle Kristine
    Germa, Caroline
    Hirawat, Samit
    O'Shaughnessy, Joyce
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] Patterns of resource utilization and cost for postmenopausal women with hormone-receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) in Europe.
    Jerusalem, Guy Heinrich Maria
    Neven, Patrick
    Marinsek, Nina
    Zhang, Jie
    Degun, Ravi
    Benelli, Giancarlo
    Saletan, Stephen
    Andre, Fabrice
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345